Avenue Therapeutics, Inc. - ATXI Book Valuation of Business
The available price action vector for Avenue Therapeutics (ATXI) reflects asset dynamics with a metric currently at 0.00. Avenue Therapeutics (ATXI) is implementing bioethical standards in the development of neuropsychiatric agents to minimize environmental impact. The developer has earned recognition for researching safe opioid alternatives. The business is currently focusing on patenting hospital-grade drug formulations to protect its position against expansion by manufacturers of low-cost generics.
&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_ATXI_-_Avenue-Therapeutics_-_Company-Book-Value "ATXI Avenue Therapeutics Inc. Accounting Capitalization (07/04/2022 - 03/29/2025) | 👁️GURU.Markets👁️")
ATXI (Avenue Therapeutics, Inc.): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- issuer market value details:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Capital Avenue Therapeutics|ATXI - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Avenue Therapeutics Inc.|ATXI - Company Debts|Debts to Book Value Avenue Therapeutics Inc.|ATXI - Company Long-Term Debts|Company Short-Term Debts Avenue Therapeutics|Quick Liquidity avenuetx.com
- earnings and valuation multiples information:
Initial company analysis:ATXI, Avenue Therapeutics Inc
To identify fundamental stability drivers, investors should analyze the difference between a firm's total assets and all liabilities, which reflects the actual value of net assets. This book value metric demonstrates the tangible basis of Avenue Therapeutics (ATXI), confirming the company's financial capacity to sustain R&D initiatives and retain leading CNS researchers through long-term option programs.
Competitor analysis for Avenue Therapeutics
BIIB (Biogen Idec) - Accounting Capitalization|NBIX: Book Capitalization|RGC - Book Valuation of Business|Company Book Value Axsome Therapeutics, Inc.|Accounting Capitalization ACAD (ACADIA Pharma)|Book Capitalization XENE|VKTX - Total Stockholders' Equity|Supernus Pharmaceuticals - Company Net Assets|Book Capitalization catalystpharma.com CPRX|DNLI - Company Book Value|Accounting Value of Company HRMY (Harmony Biosciences Inc)|Biohaven Pharmaceutical (BHVN) - Company Book Value|Total Stockholders' Equity Amylyx Corp (AMLX)|TRVI (Trevi Therapeutics) - Book Capitalization|Book Capitalization praxismedicines.com|Company Net Assets AVXL (Anavex Life Sciences Corp.)|Company Book Value CBLL (CeriBell Inc)|Book Capitalization PRTA (prothena.com)|Alector Inc. (ALEC) - Total Stockholders' Equity|ANNX - Company Book Value|OMER (Omeros Corporation) - Accounting Capitalization|NGNE (Neurogene) - Company Net Assets|AC Immune S.A. (ACIU) - Book Capitalization|VYGR (Voyager Pharma) - Book Capitalization|Total Stockholders' Equity Neumora Corp NMRA|Company Net Assets SCLX (Scilex Holding Company)|TVGN (tevogen.com) - Accounting Value of Company|Alpha Cognition Inc. - Company Net Assets|Total Net Assets CGTX (cogrx.com)|Inhibikase - Book Capitalization|Accounting Value of Company SAVA (Cassava Pharma)|ASRT: Book Capitalization|Total Stockholders' Equity Coya Therapeutics (COYA)|Company Book Value VistaGen Therapeutics, Inc.|OVID: Accounting Value of Company|Book Capitalization ABOS|Book Capitalization CervoMed Corporation (CRVO)|Company Book Value Alterity Therapeutics Limited ATHE|CLNN (Clene Inc) - Net Asset Value|PepGen Corp - Book Capitalization|Total Stockholders' Equity jupiterneurosciences.com|RLMD (Relmada) - Company Net Assets|Annovis Bio Corporation (ANVS) - Book Capitalization|Company Net Assets GRCE|AIFF (fireflyneuro.com) - Total Net Assets|Book Capitalization KLTO|Book Valuation of Business neurosense-tx.com|Book Capitalization RVPH (Reviva Pharmaceuticals Holdings)|MTVA - Company Net Assets|NRXS - Company Book Value|Book Valuation of Business Helius Medical HSDT|PASG: Book Capitalization|Neuphoria Therapeutics (NEUP) - Book Capitalization|Company Net Assets NERV|ATHA (Athira Pharma Corp) - Total Net Assets|Company Net Assets ADXN (Addex Therapeutics)|alzamend.com - Accounting Capitalization|Book Capitalization CYCN (Cyclerion Therapeutics, Inc.)|Book Valuation of Business Protagenic Therapeutics Inc. (PTIX)|KTTA - Company Book Value|CRGT (Cortigent, Inc.) - Accounting Capitalization|BCLI: Book Capitalization|Total Stockholders' Equity caratherapeutics.com (CARA)|Company Net Assets CHRO|Book Capitalization Eliem|Company Book Value Intra-Cellular Therapies (ITCI)|LBPH (Longboard) - Accounting Value of Company|Company Book Value Marinus Pharmaceuticals MRNS|nkgenbiotech.com (NKGN) - Total Stockholders' Equity|NeuroBo Pharmaceuticals, Inc. - Book Capitalization|SAGE - Book Capitalization|SNPX (Neurotrope) - Company Net Assets|TRVN (Trevena Inc) - Company Book Value|VIGL (Vigil Neuroscience Inc.) - Book Capitalization|Total Stockholders' Equity Anew Medical Inc. WENA|Company Book Value Cerevel Therapeutics, Inc. (CERE)